ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,969.34
0.35%
Dow Jones
44,296.51
0.97%
US Dollar vs MXN
20.4285
0.00%
Brent Oil
74.65
0.00%
Bitcoin
98,275.43
0.50%
Pepperstone
Advertisement
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Sonnet BioTherapeutics Holdings Inc (SONN)

  7. Sonnet BioTherapeutics Holdings Inc (SONN) Noticias

SONN

Sonnet BioTherapeutics (SONN)

Sonnet BioTherapeutics Holdings Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:SONN
FechaHoraFuenteTítuloSímboloCompañía
12/11/202408:15GlobeNewswire Inc.Sonnet BioTherapeutics Releases Virtual Investor ‘”What this Means” SegmentNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
08/11/202407:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
07/11/202408:22Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:SONNSonnet BioTherapeutics Holdings Inc
06/11/202423:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
06/11/202412:20GlobeNewswire Inc.Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq RulesNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
06/11/202408:22Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:SONNSonnet BioTherapeutics Holdings Inc
06/11/202407:30GlobeNewswire Inc.Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug CandidatesNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
28/10/202408:01Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:SONNSonnet BioTherapeutics Holdings Inc
17/10/202407:45GlobeNewswire Inc.Sonnet BioTherapeutics Inc. Regains Compliance with NasdaqNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
09/10/202407:45GlobeNewswire Inc.Sonnet BioTherapeutics Inc. Enters into Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080 for Diabetic Peripheral Neuropathy (DPN) in IndiaNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
04/10/202407:30GlobeNewswire Inc.Sonnet BioTherapeutics to Receive Non-Dilutive Funding Through New Jersey Tax Certificate Transfer and Australia R&D Tax Incentive ProgramsNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
30/09/202408:00GlobeNewswire Inc.Sonnet BioTherapeutics Announces Launch of CEO Corner PlatformNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
25/09/202407:30GlobeNewswire Inc.Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock SplitNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
18/09/202407:30GlobeNewswire Inc.Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid TumorsNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
04/09/202408:15GlobeNewswire Inc.Sonnet BioTherapeutics to Participate in the Virtual Investor Closing Bell SeriesNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
19/08/202416:28Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
19/08/202416:27Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
19/08/202407:45GlobeNewswire Inc.Sonnet BioTherapeutics Enters into Clinical Collaboration Agreement to Commence Investigator-Initiated and Funded Phase 1/2a Study of SON-1210 in Combination with Chemotherapy for the Treatment of Pancreatic CancerNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
14/08/202407:45Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SONNSonnet BioTherapeutics Holdings Inc
14/08/202407:35GlobeNewswire Inc.Sonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate UpdateNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
09/08/202416:28Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
24/07/202407:30GlobeNewswire Inc.Sonnet BioTherapeutics Reports Encouraging Data from Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) That Support Advancement into Phase 2 StudyNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
15/07/202416:05Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:SONNSonnet BioTherapeutics Holdings Inc
20/06/202407:30GlobeNewswire Inc.Sonnet BioTherapeutics Announces Exercise of Warrants for $3.4 Million in Gross ProceedsNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
13/06/202407:00GlobeNewswire Inc.Sonnet BioTherapeutics Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, SON-1411 and SON-1400, Each Containing a Variant IL-18 DomainNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
28/05/202407:00GlobeNewswire Inc.Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual MeetingNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
02/01/202415:19Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SONNSonnet BioTherapeutics Holdings Inc
22/12/202315:31Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:SONNSonnet BioTherapeutics Holdings Inc
14/12/202316:02Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:SONNSonnet BioTherapeutics Holdings Inc
27/10/202319:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
 Showing the most relevant articles for your search:NASDAQ:SONN

Su Consulta Reciente

LSE
RECI
Real Estate Credit Inves...
EU
MLEDR
Eaux De Royan
BMF
DIIF28N28
DIIF28N28 - 01/2028
TG
N7T
Nutrien
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados